Clinical Trial Update: Phase I/II Trial of Modified Vaccinia Virus Ankara (MVA) Vaccine Against Smallpox [Phase 1]

View source ↗

Summary

A Phase I/II trial of a Modified Vaccinia Virus Ankara (MVA) vaccine against smallpox in healthy participants has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Smallpox

Drugs mentioned

• Modified Vaccinia Virus Ankara (MVA) vaccine against smallpox (Modified Vaccinia Ankara)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Healthy | Phase 1 | Status: COMPLETED